Popular Articles

Screening Of Second Primary Colorectal Cancers In Cancer Survivors: Cost-Effective Strategy
To suggest a feasible economic strategy for second primary colorectal cancer screening of cancer survivors in Korea, A research group constructed a decision-analytic model, compared cost-effectiveness results of cancer screening in male cancer survivors. All non-dominant strategies were those using colonoscopy in both cancer survivors and the general population, and more strict and frequent recommendation of colonoscopy, colonoscopy every 5 years and every 3 years, could be considered as economic strategies for male cancer survivors.

Genes From Man's Best Friend May Help In The Search For A Cure For Brain Cancer
Pinpointing the genes involved in human brain cancer can be like looking for a needle in a haystack, and sometimes the needle you find may not be the right one. By comparing human and canine genomes, researchers at North Carolina State University have discovered that a gene commonly believed to be involved in meningiomas-tumors that affect the meninges, or thin covering, of the human brain and account for one out of four adult brain tumors -may not be as key for tumor formation as previously thought, and they"ve narrowed the search for the real culprit.
News of the day
Subclinical Markers Predict Relapse In Juvenile Idiopathic Arthritis Post Methotrexate Withdrawal
Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate (MTX) therapy in children with juvenile idiopathic arthritis (JIA) who have achieved inactive disease status, according to a new study presented at PReS 2009, a joint congress with the 2009 Congress of the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
Public Health

Brain Irradiation In Lung Cancer

A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1. "With improved treatments for non-small cell lung cancer, patients are living longer and we are seeing more brain metastases," says study author Elizabeth Gore, M.D. "This study compared the efficacy of prophylactic (preventive) cranial irradiation (PCI) vs. observation in these patients, and found that those not receiving cranial irradiation were two and one-half times more likely to develop brain metastasis than those who did." The study analyzed 356 patients. While the results did not show a statistically significant difference in survival between the two groups, it did show that PCI significantly decreased the incidence of brain metastases during the first year post-treatment. Dr. Gore anticipates that additional study of the impact of PCI -- on neuro-psychological function and quality of life in these patients -- will help determine if use of PCI should become standard care. Dr. Gore is associate professor of radiation oncology at the Medical College. Co investigators included K. Bae, of the Radiation Therapy Oncology Group, Philadelphia, PA; Stuart Wong, M.D. of the Medical College of Wisconsin; J. Bonner of the University of Alabama at Birmingham; A. Sun, of the Princess Margaret Hospital, University Health Network, University of Toronto; S. Schild of the Mayo Clinic Arizona in Scottsdale; L. E. Gaspar of the University of Colorado Cancer Center in Aurora; J. Bogart of SUNY Health Science Center at Syracuse, NY; M. Werner-Wasik of Thomas Jefferson University Hospital in Philadelphia, and H. Choy, University of Texas Southwestern Medical Center in Dallas. The research was funded by Grants from the National Cancer Institute. Toranj Marphetia Medical College of Wisconsin


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):